Endocrine Today Current Issue

The following articles appeared in the print edition of Endocrine Today.

Table of Contents

• Rising diabetes prevalence in low-income countries ‘alarming and discouraging’ Michael Monostra
• Adherence to anti-obesity drugs, engagement with behavioral programs key to weight loss Erin T. Welsh, MA
• Adults experience less fear, worry after surgery for low-risk papillary thyroid cancer Michael Monostra
• Adults with obesity lost 22.7% of body weight with combination GLP-1/amylin analog Michael Monostra
• DKA concerns remain paramount in FDA’s denial of sotagliflozin for type 1 diabetes Michael Monostra
• Drug shortages, CGM use in type 2 diabetes among updates in ADA 2025 Standards of Care Michael Monostra
• Famed CDC journal goes unpublished amid HHS communications freeze Gerard Gallagher; Caitlyn Stulpin; Stephen I. Feller
• Fatty muscle a cardiovascular risk factor independent from BMI Scott Buzby
• FDA approves a generic form of liraglutide to treat type 2 diabetes
• FDA approves Zepbound for moderate to severe OSA, obesity Kate Young
• FDA confirms end of tirzepatide shortage
• FDA expands setmelanotide approval for rare forms of obesity to children aged 2 to 5 years
• GLP-1 receptor agonists tied to similar thyroid cancer risk as DPP-IV inhibitors Michael Monostra
• High phthalate, plasticizer metabolite concentrations tied to metabolic syndrome in young Erin T. Welsh, MA
• ‘Increasingly common’ type 2 diabetes in pregnancy drives perinatal mortality risk Erin T. Welsh, MA
• ‘It may save lives’: CGM use cuts mortality risk in type 1, type 2 diabetes Michael Monostra
• Lack of Lp(a) screening a ‘missed opportunity’; promising therapies on the horizon Scott Buzby
• Lancet report offers a ‘new reframing’ for defining, diagnosing obesity Michael Monostra
• Medicare selects 15 drugs for second round of price negotiations, including semaglutide
• Mediterranean diet, low exposure to organic pollutants reduces gestational diabetes risk Moira Mahoney
• Mifepristone reduces HbA1c in patients with hypercortisolism, type 2 diabetes Erik Swain
• New error grid better tailored to assess CGM accuracy Michael Monostra
• Newer obesity drugs alter appetite feedback control, allow greater long-term weight loss Michael Monostra
• Novel drug confers weight loss of up to 20% at 1 year in phase 2 study Erik Swain
• Novel obesity drug induces up to 22% weight loss with no safety concerns
• Osteoporosis prevalence high for all races, incomes undergoing lung cancer screening Erin T. Welsh, MA
• Q&A: Oncofertility innovator awarded National Medal of Science Michael Monostra; Teresa K. Woodruff, PhD
• Race, sex disparities persist in weight-loss surgery Erik Swain
• Relacorilant improves cardiometabolic metrics for patients with Cushing’s syndrome Erik Swain
• Sarcopenia unlikely for most after weight loss, but more data needed on older adults Michael Monostra
• STEP UP: High-dose semaglutide led to 21% weight loss for adults with obesity Michael Monostra
• Sugary drinks linked to millions of new diabetes, cardiovascular disease cases worldwide Andrew (Drew) Rhoades
• Vitamin D, calcium supplements may decrease blood pressure in older adults with obesity Moira Mahoney
• Younger age at type 2 diabetes diagnosis tied to higher dementia risk Erin T. Welsh, MA
• Zoledronate infusions every 5 years may lower fracture risk for early postmenopausal women Michael Monostra